Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TransCon PTH

            Therapeutic Area: Endocrinology Product Name: TransCon PTH

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 02, 2021

            Details:

            The primary endpoints of the study include evaluating the safety, tolerability and efficacy of once-daily subcutaneous injection of TransCon™ PTH in adults with HP.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TransCon PTH

            Therapeutic Area: Endocrinology Product Name: TransCon PTH

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Ascendis Pharma

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 30, 2021

            Details:

            The multicenter, randomized, open-label and parallel control study aims to demonstrate noninferiority in annualized height velocity following weekly injections of TransCon hGH compared to once daily dosing of hGH after 52 weeks of treatment in prepubertal children with GHD.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TransCon hGH

            Therapeutic Area: Endocrinology Product Name: TransCon hGH

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Sequoia China

            Deal Size: $150.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing January 09, 2021

            Details:

            Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong foundation for commercialization.